share_log

10-K: FY2023 Annual Report

10-K: FY2023 Annual Report

10-K：2023財年年報
美股sec公告 ·  04/16 17:11
Moomoo AI 已提取核心訊息
SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.
SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.
醫療科技公司SeaStar Medical報告稱，截至2023年12月31日的一年中出現淨虧損2620萬美元，比上一年的淨虧損1220萬美元增長115%。公司的累計赤字從去年的8850萬美元增加至約11470萬美元。研發費用增加139%，達到597.3萬美元，主要是由於臨床試驗費用和人員工資增加，而一般和管理費用由於保險費、SEC報告費和法律費用增加19%，達到823.7萬美元。SeaStar Medical尚未從商業化產品中獲得重大收入，其運營主要通過股權證券、可轉換債券和撥款進行融資。截至2023年12月31日，該公司的現金餘額約爲20萬美元，而上一年爲0萬美元。SeaStar Medical的未來計劃包括繼續開發其選擇性細胞穀物裝置（SCD）以獲得FDA批准和最終商業化。然而，該公司承認需要額外的資金支持其運營，並且籌集這樣的資金是否有利可圖仍存在不確定性。
醫療科技公司SeaStar Medical報告稱，截至2023年12月31日的一年中出現淨虧損2620萬美元，比上一年的淨虧損1220萬美元增長115%。公司的累計赤字從去年的8850萬美元增加至約11470萬美元。研發費用增加139%，達到597.3萬美元，主要是由於臨床試驗費用和人員工資增加，而一般和管理費用由於保險費、SEC報告費和法律費用增加19%，達到823.7萬美元。SeaStar Medical尚未從商業化產品中獲得重大收入，其運營主要通過股權證券、可轉換債券和撥款進行融資。截至2023年12月31日，該公司的現金餘額約爲20萬美元，而上一年爲0萬美元。SeaStar Medical的未來計劃包括繼續開發其選擇性細胞穀物裝置（SCD）以獲得FDA批准和最終商業化。然而，該公司承認需要額外的資金支持其運營，並且籌集這樣的資金是否有利可圖仍存在不確定性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息